Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Candel Therapeutics not addressing metastatic PDAC

<< Previous

Bullboard Posts

Next >>

Comment by Peladawnon Apr 04, 2024 5:34pm

129 Views

Post# 35971467

RE:RE:RE:RE:RE:RE:Candel Therapeutics not addressing metastatic PDAC

Thanks for that, Note.....sure makes ya wonder what percentage Oncy share price will rise the day they announce results from Goblet with patients still alive and still going strong.....And then the commencement of enrollment in one or maybe even both of the Phase 3 trials.

<< Previous

Bullboard Posts

Next >>

Day trading vs. swing trading strategies for small-cap stocks